23948sdkhjf
Logga in eller skapa för att spara artiklar
Få tillgång till allt innehåll på Life Science Sweden
Ingen bindningstid eller kortinformation krävs
Gäller endast personlig prenumeration.
Kontakta oss för en företagslösning.

Novo Nordisk appoints Mike Doustdar as new CEO

The Danish pharmaceutical giant Novo Nordisk has appointed Mike Doustdar as its new CEO. At the same time, the company announced it was lowering its forecasts – which caused the stock to drop sharply on Wednesday.

Mike Doustdar, who will take office on August 7, is currently Novo Nordisk’s Executive Vice President of International Operations. Under his leadership, this division has more than doubled its sales over the past decade, reaching nearly 112 billion Danish kroner last year.

"We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams", said Novo Nordisk Chair Helge Lund in a pressrelease.

BREAKING
{{ article.headline }}
0.094